Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up study of BI 3720931 in cystic fibrosis
NL-OMON59165Phase 2Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2025
- Modality
- Lentiviral Vectors → Retroviral Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Lenticlair-ON in cystic fibrosis (CF), sponsored by Boehringer Ingelheim. Primary endpoint: Occurrence of treatment-emergent delayed adverse events. Started Oct 2025; status: active, not recruiting.
02
Drugs
Lenticlair-ON
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON59165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59165.